Today, on 3 February 2026, the extraordinary general meeting was held in EQL Pharma AB. A summary of the adopted resolution follows below.
Resolution on implementation of a long-term incentive program
The extraordinary general meeting resolved in accordance with the proposal from the board of directors to implement a long-term incentive program for two key employees based on issue of warrants.
The incentive program comprises a maximum of 220,000 warrants. Each warrant entitles the right to subscribe for one new share in the company at a subscription price per share corresponding to 200 per cent of the volume weighted average price according to Nasdaq Stockholm's official price list for shares in the company during the ten trading days that follows immediately after the publication of the company's interim report for April - December 2025. The warrants shall be issued to the fair market value of the warrants at the time of subscription, which shall be determined by Optionspartner as independent valuation institute in accordance with the Black & Scholes valuation formula. Subscription of shares by virtue of the warrants may be effected from and including 2 September 2030 to and including 16 September 2030.
In case all warrants issued in connection with the incentive program are exercised for subscription of new shares, a total of 220,000 new shares will be issued, which corresponds to a dilution of approximately 0.74 per cent of the company's share capital and votes.
Lund on 3 February 2026
EQL Pharma AB (publ)
The information was submitted, through the agency of the contact person set out above, for publication on 03-02-2026 14:15 CET.
For more information contact:
Axel Schörling,
CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com
EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 47 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2026 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm stock market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.
